title: Nintedanib in NSCLC: evidence to date and place in therapy.
abstract: The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc. Those patients who are wildtype for known and valuable oncogenes can receive standard chemotherapy as first-line treatment, with the possibility of adding bevacizumab. With regard to second-line treatment, nintedanib can improve the efficacy of docetaxel. Nintedanib is a tyrosine kinase inhibitor targeting three angiogenesis-related transmembrane receptors. The usefulness of nintedanib as an anticancer agent for NSCLC has been proved by both preclinical and clinical phase I and II trials; however, its approval for the use in clinical practice has been possible because of the positive results of the LUME-Lung 1 trial (nintedanib + docetaxel versus docetaxel alone) in terms of progression-free survival and overall survival, and a manageable tolerability profile. Therefore, the good results seen in the clinical trials with nintedanib in the second-line setting for NSCLC patients with adenocarcinoma subtype are encouraging enough to recommend it in clinical practice.
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Bronte
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Passiglia
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Galvano
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Nadia
authors.initials: N
authors.lastname: Barraco
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Angela
authors.initials: A
authors.lastname: Listì
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Marta
authors.initials: M
authors.lastname: Castiglia
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Sergio
authors.initials: S
authors.lastname: Rizzo
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Fiorentino
authors.affiliation: Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Italy.
authors.forename: Viviana
authors.initials: V
authors.lastname: Bazan
authors.affiliation: Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Russo
keywords: FGFR; NSCLC; PDGFR; VEGFR; angiogenesis; nintedanib; targeted therapy